JPWO2019165156A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019165156A5 JPWO2019165156A5 JP2020543928A JP2020543928A JPWO2019165156A5 JP WO2019165156 A5 JPWO2019165156 A5 JP WO2019165156A5 JP 2020543928 A JP2020543928 A JP 2020543928A JP 2020543928 A JP2020543928 A JP 2020543928A JP WO2019165156 A5 JPWO2019165156 A5 JP WO2019165156A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- domain
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 102100035793 CD83 antigen Human genes 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 4
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 4
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 4
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 4
- 230000019491 signal transduction Effects 0.000 claims 3
- 108010052382 CD83 antigen Proteins 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 239000012642 immune effector Substances 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000031146 intracellular signal transduction Effects 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 101710145634 Antigen 1 Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634435P | 2018-02-23 | 2018-02-23 | |
| US62/634,435 | 2018-02-23 | ||
| US201862677783P | 2018-05-30 | 2018-05-30 | |
| US62/677,783 | 2018-05-30 | ||
| PCT/US2019/019065 WO2019165156A1 (en) | 2018-02-23 | 2019-02-22 | Cd83-binding chimeric antigen receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513857A JP2021513857A (ja) | 2021-06-03 |
| JPWO2019165156A5 true JPWO2019165156A5 (enExample) | 2022-02-28 |
| JP7358369B2 JP7358369B2 (ja) | 2023-10-10 |
Family
ID=67686942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543928A Active JP7358369B2 (ja) | 2018-02-23 | 2019-02-22 | Ｃｄ８３結合キメラ抗原受容体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12492254B2 (enExample) |
| EP (1) | EP3755722A4 (enExample) |
| JP (1) | JP7358369B2 (enExample) |
| KR (1) | KR20200130324A (enExample) |
| CN (1) | CN112004832A (enExample) |
| AU (1) | AU2019226101A1 (enExample) |
| BR (1) | BR112020017015A2 (enExample) |
| IL (1) | IL276836A (enExample) |
| MA (1) | MA51917A (enExample) |
| MX (1) | MX2020008803A (enExample) |
| PH (1) | PH12020500632A1 (enExample) |
| SG (1) | SG11202007755YA (enExample) |
| WO (1) | WO2019165156A1 (enExample) |
| ZA (1) | ZA202005837B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020008803A (es) | 2018-02-23 | 2021-01-15 | H Lee Moffitt Cancer Ct & Res | Receptores de antígenos quiméricos que se unen a cd83. |
| US20220289862A1 (en) * | 2019-08-16 | 2022-09-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Anti-cd83 chimeric antigen receptor expressing t regulatory cells |
| CA3147835A1 (en) * | 2019-08-16 | 2021-02-25 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptors for treating myeloid malignancies |
| US11802159B2 (en) * | 2019-09-30 | 2023-10-31 | The Trustees Of The University Of Pennsylvania | Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs) |
| US20230051885A1 (en) * | 2019-12-18 | 2023-02-16 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Systems and Methods for Producing Efficacious Regulatory T Cells |
| EP4093767A1 (en) * | 2020-01-22 | 2022-11-30 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor |
| US20230107770A1 (en) * | 2020-02-20 | 2023-04-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of enhancing immunotherapy using er stress pathway inhibitors |
| WO2022036224A1 (en) * | 2020-08-14 | 2022-02-17 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptor t cells for treating autoimmunity |
| CN119331093B (zh) * | 2024-11-04 | 2025-07-11 | 武汉伊莱瑞特生物科技股份有限公司 | 一种抗CD30的兔源Fab抗体及其制备方法和应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040185040A1 (en) | 2001-11-21 | 2004-09-23 | Celltech R & D Limited | Modulating immune responses |
| EP1572976B1 (en) | 2002-11-21 | 2010-09-15 | Celltech R & D, Inc. | Modulating immune responses |
| GB0624500D0 (en) | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US9228172B2 (en) | 2008-06-19 | 2016-01-05 | The Trustees Of The University Of Pennsylvania | Inducible regulatory T-cell generation for hematopoietic transplants |
| WO2012096974A1 (en) | 2011-01-10 | 2012-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of allogeneic hematopoietic stem cell transplantation |
| JP2013150592A (ja) * | 2011-07-01 | 2013-08-08 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| JP2013040160A (ja) * | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| AU2014213009B2 (en) | 2013-02-01 | 2019-01-03 | Kira Biotech Pty Limited | Anti-CD83 antibodies and use thereof |
| AU2014223602C1 (en) | 2013-02-26 | 2018-11-08 | Axiomx, Inc. | Methods for the production of libraries for directed evolution |
| KR102483333B1 (ko) | 2013-09-13 | 2022-12-29 | 솔리제닉스, 인크. | 경구 점막염 치료에 사용하기 위한 신규한 펩티드 및 유사체 |
| EP3209695A4 (en) * | 2014-10-23 | 2018-05-30 | DendroCyte BioTech Pty Ltd | Cd83 binding proteins and uses thereof |
| AU2015338984A1 (en) | 2014-10-31 | 2017-04-27 | The Trustees Of The University Of Pennsylvania | Methods and compositions for modified T cells |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US11161907B2 (en) * | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| JP6961490B2 (ja) | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| EP3307282A4 (en) | 2015-06-12 | 2019-05-01 | Immunomedics, Inc. | DISEASE THERAPY WITH CONSTRUCTS OF CHIMERIC ANTIGEN RECEPTOR (CAR) AND T-CELL (CAR-T) OR NK-CELL (CAR-NK) EXPRESSIVE CAR CONSTRUCTS |
| CN115058395B (zh) | 2015-06-25 | 2025-07-18 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| JP2019535262A (ja) | 2016-11-11 | 2019-12-12 | オートラス リミテッド | キメラ抗原受容体 |
| WO2019051541A1 (en) | 2017-09-13 | 2019-03-21 | Dendrocyte Biotech Pty Ltd | Treatment method |
| CA3076337A1 (en) | 2017-09-19 | 2019-03-28 | Massachusetts Institute Of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
| TW201922774A (zh) | 2017-11-15 | 2019-06-16 | 瑞士商諾華公司 | 標靶bcma嵌合抗原受體、標靶cd19嵌合抗原受體及組合療法 |
| WO2019136335A1 (en) | 2018-01-05 | 2019-07-11 | Gencyte Therapeutics, Inc. | Precision molecular adaptor system for car-t immunotherapy |
| PL3749334T3 (pl) | 2018-02-08 | 2025-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Allogeniczne przeszczepienie krwiotwórczych komórek macierzystych |
| MX2020008803A (es) | 2018-02-23 | 2021-01-15 | H Lee Moffitt Cancer Ct & Res | Receptores de antígenos quiméricos que se unen a cd83. |
| US20200108098A1 (en) | 2018-02-23 | 2020-04-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Anti-cd83 chimeric antigen receptor expressing t regulatory cells |
| WO2020109953A1 (en) | 2018-11-30 | 2020-06-04 | Janssen Biotech, Inc. | Gamma delta t cells and uses thereof |
| US20220289862A1 (en) | 2019-08-16 | 2022-09-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Anti-cd83 chimeric antigen receptor expressing t regulatory cells |
| US20230051885A1 (en) | 2019-12-18 | 2023-02-16 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Systems and Methods for Producing Efficacious Regulatory T Cells |
| EP4093767A1 (en) | 2020-01-22 | 2022-11-30 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor |
| WO2023122643A1 (en) | 2021-12-22 | 2023-06-29 | Regents Of The University Of Minnesota | Cd83 and allo- and autoimmune conditions |
| JP2024102735A (ja) | 2023-01-19 | 2024-07-31 | セイコーエプソン株式会社 | 頭部装着型表示装置及び光学ユニット |
-
2019
- 2019-02-22 MX MX2020008803A patent/MX2020008803A/es unknown
- 2019-02-22 WO PCT/US2019/019065 patent/WO2019165156A1/en not_active Ceased
- 2019-02-22 MA MA051917A patent/MA51917A/fr unknown
- 2019-02-22 CN CN201980027877.0A patent/CN112004832A/zh active Pending
- 2019-02-22 JP JP2020543928A patent/JP7358369B2/ja active Active
- 2019-02-22 SG SG11202007755YA patent/SG11202007755YA/en unknown
- 2019-02-22 BR BR112020017015-1A patent/BR112020017015A2/pt unknown
- 2019-02-22 EP EP19757555.8A patent/EP3755722A4/en active Pending
- 2019-02-22 US US16/969,056 patent/US12492254B2/en active Active
- 2019-02-22 KR KR1020207027148A patent/KR20200130324A/ko not_active Ceased
- 2019-02-22 AU AU2019226101A patent/AU2019226101A1/en not_active Abandoned
-
2020
- 2020-08-19 PH PH12020500632A patent/PH12020500632A1/en unknown
- 2020-08-20 IL IL276836A patent/IL276836A/en unknown
- 2020-09-21 ZA ZA2020/05837A patent/ZA202005837B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021087455A5 (enExample) | ||
| JP2021177771A5 (enExample) | ||
| JP2021094037A5 (enExample) | ||
| JP2025028239A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| JP2019527557A5 (enExample) | ||
| JP2020517295A5 (enExample) | ||
| JP2020114264A5 (enExample) | ||
| JP2025032091A5 (enExample) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| JP2024023228A5 (enExample) | ||
| TW201920653A (zh) | 調節細胞表達的生物活性之結合分子 | |
| IL277398B2 (en) | Pd-l1 binding affimers, and uses related thereto | |
| JP2020530289A5 (enExample) | ||
| JP2017524367A5 (enExample) | ||
| IL301527A (en) | METHODS FOR SELECTIVE EXPANSION OF ɣδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF | |
| JP2020513754A5 (enExample) | ||
| JP7590034B2 (ja) | Ｎｋｇ２ａを標的にする抗体及びその使用 | |
| JPWO2019165156A5 (enExample) | ||
| JPWO2020228825A5 (enExample) | ||
| JPWO2019245991A5 (enExample) | ||
| JPWO2022081516A5 (enExample) | ||
| JPWO2021034689A5 (enExample) | ||
| JPWO2020198531A5 (enExample) | ||
| JPWO2023274384A5 (enExample) |